Takeda Pharmaceutical Co Ltd ADR (TAK) — Quality & forensics

As of 2026-09-03 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

49 /100 composite · 7 modules · general weight set

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

0.58 Altman Z-Score

Sits in the distress zone (below 1.81). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

6/9 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

-2.37 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.

FAQ · from the current data · as of 2026-09-03

Quick answers

What is Takeda Pharmaceutical Co Ltd ADR's Closelook quality reading?

The composite reads 49/100 across 7 modules, as of 2026-09-03: valuation 82, quality 34, growth 31, balance sheet 26, cash quality 56, capital allocation 74, momentum 65. Closelook scores are research diary readings, not ratings or investment advice.

What is Takeda Pharmaceutical Co Ltd ADR's Altman Z-Score?

0.58, which sits in the distress zone (below 1.81) as of 2026-09-03. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Takeda Pharmaceutical Co Ltd ADR's Piotroski F-Score?

6 of 9, as of 2026-09-03. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does Takeda Pharmaceutical Co Ltd ADR's Beneish M-Score indicate?

-2.37 — below the −1.78 manipulation-risk threshold, as of 2026-09-03. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.

Related in the Closelook universe